MedTrace Logo

Systemic Stress Prevention Via Application SysLife© for Companies

NCT05828693 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2024-05-08

No results posted yet for this study

Summary

The purpose of this study is to investigate the efficacy of systemic stress prevention via SysLife© application in a prospective, interventive, balanced, monocentric, explanatory pilot randomized controlled trial (RCT), with participants' subjective stress experience as the primary endpoint.

Research Question: Which implementations are necessary, based on the experience from this pilot RCT, to ensure the quality of a subsequent confirmatory RCT?

Hypothesis: We expect improvement of participants' subjective stress experience, goal achievement, systemic functioning in private and organisational social systems while using the SysLife© application.

Conditions

  • Stress, Psychological
  • Stress, Systemic
  • Application

Interventions

BEHAVIORAL

SysLife©

Use of the SysLife© application, with 2-, 4-, 6- and 8-month follow-up.

BEHAVIORAL

SysLife©, as intervention after closing the RCT-design

Use of the SysLife© application after 4-month waiting period, with 2- and 4-month follow-up.

Sponsors & Collaborators

  • Sysba solutions GmbH

    collaborator UNKNOWN

  • Murtfeldt Kunststoffe GmbH & Co. KG

    collaborator UNKNOWN

  • University of Witten/Herdecke

    lead OTHER

Principal Investigators

  • Christina Hunger-Schoppe, Prof. Dr. · University of Witten/Herdecke

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-29
Primary Completion
2024-03-01
Completion
2024-05-01

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05828693 on ClinicalTrials.gov